Abstract
Asthma can place considerable restrictions on the healthrelated quality of life of asthma patients and their families;
this burden may be greatest when symptoms are not
adequately controlled. The Symbicort Adjustable Maintenance Dosing Programme, consisting of studies from
several different countries, compared a guided selfmanagement plan that allows adjustable maintenance
dosing using budesonide/formoterol in a single inhaler
(Symbicort) with fixed dosing. Quality of life was assessed
in three countries, using asthma-specific and generic questionnaires. Clinically relevant improvements in mean quality of life scores were observed from the beginning to the
end of the 1-month run-in, which were maintained or
further improved during randomised treatment in both
groups. A modified patient enablement instrument was
also used in the UK study to assess patients’ feelings of
control towards their asthma. Adjustable maintenance dosing patients showed significantly (p < 0.05) greater feelings
of enablement compared with fixed dosing. These outcomes were achieved with less study drug usage, compared
with fixed dosing.
Original language | English |
---|---|
Pages (from-to) | 26-32 |
Number of pages | 7 |
Journal | International Journal of Clinical Practice |
Volume | 58 |
Issue number | s141 |
Early online date | 17 Aug 2004 |
DOIs | |
Publication status | Published - Aug 2004 |
Keywords
- health-related quality of life
- asthma
- budesonide/formoterol
- adjustable maintenance dosing
- guided self-management plans